- $15.00m
- -$7.57m
- $41.10m
- 24
- 66
- 41
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.79 | ||
| Price to Tang. Book | 0.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.37 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -42.96% | ||
| Return on Equity | -38.75% | ||
| Operating Margin | -20.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 15.76 | 36.08 | 41.09 | n/a | 8.26 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.
Directors
- Daniel Bradbury CHM (60)
- Bruce Steel PRE (54)
- Jason Keyes CFO (50)
- Christine Zedelmayer COO (51)
- Dolca Thomas EVP (50)
- Stephen Connelly CSO (39)
- Joel Rothman OTH (52)
- Martha Demski IND (68)
- Bala Manian IND (75)
- Charles Mcdermott IND (49)
- Mark Pruzanski IND (53)
- Yu Xu IND (49)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 16th, 2017
- Public Since
- October 12th, 2018
- No. of Shareholders
- 44
- No. of Employees
- 35
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 35,719,317
- Address
- 2223 Avenida de La Playa Ste 105, LA JOLLA, 92037-3217
- Web
- https://www.equilliumbio.com/home/default.aspx
- Phone
- +1 8584125302
- Auditors
- KPMG LLP
Upcoming Events for EQ
Equillium Inc Annual Shareholders Meeting
Similar to EQ
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Equillium share price?
As of Today at 20:30 UTC, shares in Equillium are trading at $0.42. This share price information is delayed by 15 minutes.
How has the Equillium share price performed this year?
Shares in Equillium last closed at $0.42 and the price had moved by -73.08% over the past 365 days. In terms of relative price strength the Equillium share price has underperformed the S&P500 Index by -75.72% over the past year.
What are the analyst and broker recommendations for Equillium?
The overall consensus recommendation for Equillium is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Equillium dividend yield?
Equillium does not currently pay a dividend.
Does Equillium pay a dividend?
Equillium does not currently pay a dividend.
When does Equillium next pay dividends?
Equillium does not currently pay a dividend.
How do I buy Equillium shares?
To buy shares in Equillium you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Equillium?
As of the previous close price of $0.42, shares in Equillium had a market capitalisation of $15.00m.
Where are Equillium shares listed?
Here are the trading details for Equillium:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: EQ
What kind of share is Equillium?
Based on an overall assessment of its quality, value and momentum Equillium is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Equillium share price forecast for 2025?
The analyst consensus target price for shares in Equillium is $1.00. That is 138.1% above the last closing price of $0.42.
Analysts covering Equillium currently have a consensus Earnings Per Share (EPS) forecast of -$0.85 for the next financial year.
Find out moreWhat is the trend in the Equillium share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Equillium. Over the past six months, its share price has underperformed the S&P500 Index by -49.17%.
As of the last closing price of $0.42, shares in Equillium were trading -45.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Equillium PE Ratio?
The Equillium PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Equillium?
Equillium's management team is headed by:
- Daniel Bradbury - CHM
- Bruce Steel - PRE
- Jason Keyes - CFO
- Christine Zedelmayer - COO
- Dolca Thomas - EVP
- Stephen Connelly - CSO
- Joel Rothman - OTH
- Martha Demski - IND
- Bala Manian - IND
- Charles Mcdermott - IND
- Mark Pruzanski - IND
- Yu Xu - IND